Absence of the cell cycle inhibitor p27(Kip1) protein predicts poor outcome in patients with stage I-III colorectal cancer

Annals of Surgical Oncology

Volumn 6, Issue 1, 1999, Pages 19-25

  Belluco, Claudio ^a   Esposito, Giovanni ^a   Bertorelle, Roberta ^a   Del Mistro, Annarosa ^a   Fassina, Ambrogio ^a   Vieceli, Giulia ^a   Chieco Bianchi, Luigi ^a   Nitti, Donato ^a   Lise, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cell cycle inhibitors.; Colorectal carcinoma; p27(Kip1) protein; Prognostic markers

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; COLORECTAL CANCER; COLORECTAL SURGERY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0033048989     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0019-2     Document Type: Article

References (25)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
3. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:322-6.
4. Labianca R, Marsoni S, Pancera G, et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995:345:939-44.
5. Jessup JM, McGinnis LS, Steele GD Jr, et al. Colon cancer: report from the National Cancer Data Base. Cancer 1996;78:918-26.
6. Willet C, Tepper JE, Cohen AM, Orlow E, Welch C, Donaldson G. Failure patterns following curative resection of colonie carcinoma. Ann Surg 1984;200:685-90.
7. Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs. C colon cancer. Results from four NSABP adjuvant studies (E01, E02, E03, E04) [abstract]. Proc Am Soc Clin Oncol 1996;15:205. Abstract 461.
8. Erlichman C, Marsoni S, Seitz JF, et al. Event free and overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of five randomised trials [abstract]. Proc Am Soc Clin Oncol 1997;16:280. Abstract 991.
9. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
10. Kip1, a cycline dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
11. Kip1 and cycline E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997;3:222-6.
12. Kip1 protein: Prognostic implications in primary breast cancer. Nature Med 1997;3:227-30.
13. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997;3:231-4.
14. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cycline-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
15. UICC. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumor. Berlin: Springer-Verlag, 1992.
16. Morson BC, Sobin LH. Histologic typing of intestinal tumors: WHO technical report No. 15. Geneva: World Health Organization, 1976.
17. Kaplan EL, Meier P. Nonparametrics estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972;34:187-220.
19. Kip1 in multistage colorectal carcinogenesis. Cancer Res 1998;114-22.
20. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-5.
21. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995;55:2266-9.
22. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitinproteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
23. Kip1 accumulation during the cell cycle. Science 1996;271:1861-4.
24. Fielding LP, Pettigrew N. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the colorectal cancer working group. Arch Pathol Lab Med 1995;119:1115-21.
25. Kip1 induces cell cycle arrest and loss of cyclineCdk activity in human breast cancer cells. Oncogene 1997;14: 2283-9.